Cover Image
市場調查報告書

馬堡病毒感染疾病 (馬堡病毒出血熱):開發中產品分析

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 484632
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
馬堡病毒感染疾病 (馬堡病毒出血熱):開發中產品分析 Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 78 Pages
簡介

馬堡病毒出血熱是會影響人類與人類以外的靈長類,罕見的急性傳染病。症狀有發燒,頭痛,發冷,衰弱,腹瀉,胃痛,體重的減少等。

本報告提供全球各國治療馬堡病毒感染疾病 (馬堡病毒出血熱)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

馬堡病毒感染疾病 (馬堡病毒出血熱);概要

馬堡病毒感染疾病 (馬堡病毒出血熱) - 治療藥的開發

  • 開發中產品 概要
  • 開發中產品:各企業
  • 開發中產品:各大學/研究機關
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Arno Therapeutics Inc
  • BioCryst Pharmaceuticals Inc
  • Emergent BioSolutions Inc
  • Fab'entech SA
  • GeoVax Labs Inc
  • Integrated BioTherapeutics Inc
  • Johnson & Johnson
  • Microbiotix Inc
  • NanoViricides Inc
  • Profectus BioSciences Inc
  • Rodos BioTarget GmbH
  • Sarepta Therapeutics Inc
  • Vaxart Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9683IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Marburg hemorrhagic fever is a rare, acute infectious which affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain and weight loss.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 5, 10 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Overview
    • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Companies Involved in Therapeutics Development
    • Arno Therapeutics Inc
    • BioCryst Pharmaceuticals Inc
    • Eisai Co Ltd
    • Emergent BioSolutions Inc
    • Fab'entech SA
    • Integrated BioTherapeutics Inc
    • Johnson & Johnson
    • NanoViricides Inc
    • Profectus BioSciences Inc
    • Rodos BioTarget GmbH
    • Sarepta Therapeutics Inc
    • Theravectys SA
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drug Profiles
    • (Ebola + Marburg) (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Ebola + Marburg) (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Ebola + Marburg) (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 1-E703 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies for Ebola and Marburg Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-5 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVI-7288 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eritoran tetrasodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • galidesivir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GreEMTri - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • infectious disease vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MR-191N - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MR-78 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NP-026 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBT-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Ebola and Marburg Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Ebola and Marburg Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit VP40 for Ebola and Marburg Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAC-69120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 19, 2016: Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial
      • Nov 17, 2015: Profectus Presents Preclinical Data Demonstrating that a Single Dose of Multi-Component Vaccine Provides Complete Protection Against Zaire and Sudan Species of Ebola Virus and Marburg Virus
      • Jul 22, 2015: Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus platform
      • May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
      • Apr 08, 2015: Profectus BioSciences Ebola Vaccine Shown Effective and Safe in Providing Rapid, Single-Dose Protection Against Current "Makona" Ebola Outbreak Strain in Non-Human Primates
      • Mar 31, 2015: BioCryst Awarded BCX4430 Advanced Development Contract
      • Mar 25, 2015: IBT Presents Pan-Ebola and Pan-Filovirus Monoclonal Antibodies
      • Jan 22, 2015: NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory
      • Dec 23, 2014: BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection
      • Oct 31, 2014: Profectus BioSciences Receives $9.5 Million Department of Defense Funding to Manufacture Trivalent VesiculoVax-Vectored Vaccine to Protect Against all Ebola and Marburg Viruses
      • Oct 27, 2014: NanoViricides Signs CRADA for Material Transfer with USAMRIID for Evaluating Its Anti-Ebola Drug Candidates
      • Sep 18, 2014: BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases
      • Jul 31, 2014: UTMB researchers receive over $6 million to develop treatment for deadly Ebola and Marburg viruses
      • Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate
      • Sep 17, 2013: BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases to Develop BCX4430 for the Treatment of Marburg Virus Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Arno Therapeutics Inc, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Eisai Co Ltd, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Fab'entech SA, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Integrated BioTherapeutics Inc, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Johnson & Johnson, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by NanoViricides Inc, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Profectus BioSciences Inc, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Rodos BioTarget GmbH, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Sarepta Therapeutics Inc, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Theravectys SA, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects, H2 2017
  • Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top